United States Patent 8,709,475: Scope, Claims, Expiration and Vascepa Patent Landscape

U.S. Patent No. 8,709,475 covers a method of treating mixed dyslipidemia by combining a statin with 2,500 mg to about 5,000 mg per day of ethyl eicosapentaenoate, commonly referred to as icosapent ethyl. The claims are directed to treatment outcomes, including reductions in fasting triglycerides, LDL-C, apolipoprotein B and VLDL-C.

The patent is a method-of-use patent rather than a composition, formulation or manufacturing patent. Its commercial significance depends on whether a competing product is labeled for use with a statin in the claimed dose range and whether the prescribed treatment produces the claimed lipid reductions.

What does U.S. Patent 8,709,475 protect?

U.S. Patent 8,709,475 protects a treatment method requiring four principal elements:

The patient has mixed dyslipidemia.
The patient receives a statin.
The patient receives 2,500 mg to approximately 5,000 mg per day of ethyl eicosapentaenoate.
The combined treatment reduces specified lipid parameters relative to statin treatment without ethyl eicosapentaenoate.

The independent claim is claim 1. Claims 2 through 9 add quantitative lipid-reduction thresholds. Claims 10 through 12 define the statin class and dosage form.

Claim group	Protected subject matter
Claim 1	Statin plus 2,500 mg to about 5,000 mg daily ethyl eicosapentaenoate for mixed dyslipidemia
Claims 2-4	At least 10%, 15% or 20% reduction in fasting triglycerides
Claim 5	At least 25% reduction in fasting triglycerides and at least 5% reduction in LDL-C
Claims 6-7	Reduction in fasting apolipoprotein B, including at least 5%
Claims 8-9	Reduction in fasting VLDL-C, including at least 15%
Claim 10	Lovastatin, mevastatin, pitavastatin, pravastatin, rosuvastatin, fluvastatin, atorvastatin or simvastatin
Claims 11-12	One or more dosage units, including capsules

The claim set does not require a particular statin dose, a particular statin brand or a specific administration time. It also does not expressly require a particular capsule strength, excipient system or manufacturing process.

What is the technical scope of the claims?

The patent is built around combination therapy for patients with mixed dyslipidemia. That condition generally involves elevated triglycerides together with abnormal cholesterol parameters, often including elevated LDL-C or non-HDL-C.

The active ingredient is ethyl eicosapentaenoate, an ethyl ester of the omega-3 fatty acid EPA. A product containing substantially pure icosapent ethyl, such as Vascepa, can fall within the active-ingredient limitation when administered at the claimed daily amount.

The dose limitation is central:

Lower boundary: 2,500 mg per day.
Upper boundary: about 5,000 mg per day.
Common commercial dose: 4,000 mg per day.

Vascepa is commonly administered as four 1-gram capsules per day or two 1-gram capsules twice daily, depending on the prescribing instructions. A 4-gram daily regimen is within the express range of claim 1.

The claims are not limited to patients with triglycerides above 500 mg/dL. They use the broader disease description of mixed dyslipidemia. That distinction matters because the FDA expanded Vascepa's approved use in 2019 to reduce cardiovascular risk in specified patients receiving maximally tolerated statin therapy and having elevated triglycerides. The patent's wording, however, should be analyzed independently from the exact wording of the FDA label.

How do the dependent claims narrow infringement risk?

Claims 2 through 9 require measured outcomes. This creates a narrower but potentially more evidence-intensive infringement theory.

For example:

Claim 2 requires at least a 10% reduction in fasting triglycerides.
Claim 4 requires at least a 20% reduction.
Claim 5 requires both at least a 25% triglyceride reduction and at least a 5% LDL-C reduction.
Claim 7 requires at least a 5% reduction in fasting apolipoprotein B.
Claim 9 requires at least a 15% reduction in fasting VLDL-C.

These limitations create two issues.

First, the comparison must be made against subjects receiving a statin without ethyl eicosapentaenoate. The comparator is not necessarily the patient's baseline lipid level. A clinical study or other evidence must establish the relative reduction against the specified statin-only population.

Second, the claim language may require evidence concerning the administered treatment and the resulting patient population. A generic label that recommends the same dose and combination may create a stronger induced-infringement case than a label that merely identifies the active ingredient without encouraging statin combination therapy.

What statins are covered by U.S. Patent 8,709,475?

Claim 10 expressly lists eight statins:

Statin	Covered by claim 10?
Lovastatin	Yes
Mevastatin	Yes
Pitavastatin	Yes
Pravastatin	Yes
Rosuvastatin	Yes
Fluvastatin	Yes
Atorvastatin	Yes
Simvastatin	Yes

The claim does not require the statin and ethyl eicosapentaenoate to be combined in one capsule. Claims 11 and 12 instead permit administration in one or more dosage units, including capsules. Separate prescriptions for a statin and icosapent ethyl can therefore be relevant to a method-of-treatment analysis.

The statutory basis for a method patent is generally 35 U.S.C. § 271(a), which addresses direct infringement, and § 271(b), which addresses inducement. A manufacturer may face greater risk if its labeling specifically instructs patients to use the product with a statin for the claimed condition.

Is U.S. Patent 8,709,475 a formulation patent?

No. The patent does not primarily protect a capsule formulation.

Claims 11 and 12 state that the ethyl eicosapentaenoate may be present in one or more dosage units and that the dosage units may comprise capsules. Those limitations identify the delivery format but do not define a detailed formulation composition.

The patent does not claim:

A particular capsule shell;
A specified excipient;
A particular purity level;
A specific dissolution profile;
A manufacturing process;
A soft-gel encapsulation process;
A particular particle-size distribution; or
A capsule containing a defined amount of EPA plus a defined inactive-ingredient system.

A competing manufacturer could therefore avoid this patent only by avoiding the claimed method, dose, indication or combination-use instructions. Changing the capsule excipients alone would not necessarily avoid infringement if the accused product is still used in the claimed treatment method.

What is the expiration date of U.S. Patent 8,709,475?

The patent issued on April 29, 2014. Its term is based on the applicable U.S. patent-term rules and the underlying priority and application history. The patent family is generally associated with an expiration date in the 2030 period.

Event	Date or period
Earliest priority period	2009
U.S. issuance	April 29, 2014
Expected ordinary term	2030 period
Status	Issued patent; term must be assessed against the official USPTO record and any term adjustment or disclaimer

The controlling source for the exact expiration calculation is the USPTO Patent Center record, including the patent-term adjustment, terminal-disclaimer and maintenance-fee data. The FDA Orange Book, where the patent is listed for an approved product, provides a separate regulatory listing date and patent-expiration entry.

A patent expiration analysis should not treat the issue date as the term end. A U.S. patent generally expires 20 years from the relevant nonprovisional filing date, subject to patent-term adjustment, terminal disclaimers, patent-term extension and priority-chain rules.

What is the Orange Book status of U.S. Patent 8,709,475?

The Orange Book status must be evaluated against the specific approved product and NDA. The relevant branded product is Vascepa, marketed by Amarin, with NDA 202057.

The key distinction is between:

Patents listed in the Orange Book for Vascepa;
Patents in the broader Amarin icosapent ethyl portfolio;
Patents asserted in Hatch-Waxman litigation; and
Patents that remain enforceable but are not listed for the relevant NDA.

A patent does not need to be an Orange Book-listed patent to have potential enforceability. Orange Book listing principally affects the ANDA applicant's certification obligations and the timing of FDA approval under the Hatch-Waxman framework.

For an ANDA applicant, a listed patent may generate:

Paragraph I certification if the patent information is not yet available;
Paragraph II certification if the patent has expired;
Paragraph III certification accepting approval after expiration; or
Paragraph IV certification alleging that the patent is invalid, unenforceable or not infringed.

The applicant's Paragraph IV notice can trigger a patent-infringement action under 35 U.S.C. § 271(e)(2).

Which companies have challenged Vascepa patents?

The principal generic challenge involved Hikma Pharmaceuticals and Dr. Reddy's Laboratories. Amarin sued generic applicants after Paragraph IV certifications concerning Vascepa patents.

The litigation centered on patents directed to icosapent ethyl, cardiovascular-risk reduction, triglyceride treatment and related uses. The litigation record included patents other than, or in addition to, U.S. Patent 8,709,475. The Federal Circuit's decision in Amarin Pharma, Inc. v. Hikma Pharmaceuticals USA Inc. addressed induced infringement and the relationship between generic labeling and protected uses.

The central commercial issue was whether a generic label that included a triglyceride indication, but omitted or narrowed a cardiovascular-risk indication, could nevertheless induce infringement of method claims. The court's analysis illustrates the importance of the label's wording, promoted uses and remaining approved indications.

What Paragraph IV risks apply to this patent?

A Paragraph IV challenge to U.S. Patent 8,709,475 would likely focus on claim construction, anticipation, obviousness, written description, enablement and infringement.

Non-infringement arguments

A generic applicant could argue that its label does not require:

Treatment of mixed dyslipidemia;
Concurrent administration with a statin;
A daily dose of at least 2,500 mg;
The claimed lipid-reduction outcome; or
Use for a protected method rather than an unprotected indication.

The outcome limitations in claims 2 through 9 may create particular non-infringement arguments because a label may not guarantee that every patient achieves a specified percentage reduction.

Invalidity arguments

Potential invalidity theories include:

Anticipation by earlier EPA or omega-3 clinical studies;
Obviousness based on combining statin therapy with high-dose EPA;
Lack of written description for the full 2,500 mg to 5,000 mg range;
Lack of enablement across all statins and all mixed-dyslipidemia populations;
Indefiniteness involving "about 5000 mg"; and
Insufficient support for relative treatment outcomes.

The strongest validity analysis depends on the patent's full specification, prosecution history, cited references and claim-construction record. The claims' comparative outcome limitations may help distinguish earlier disclosures, but they can also create evidentiary and enablement disputes.

How does this patent compare with other Vascepa patents?

U.S. Patent 8,709,475 occupies a narrower position than patents claiming the active ingredient, broader therapeutic uses or defined pharmaceutical compositions.

Patent category	Typical protection	Relevance to generic entry
Composition-of-matter	EPA or icosapent ethyl composition	Usually the broadest product-level protection, if unexpired
Method of treatment	Triglyceride reduction, cardiovascular-risk reduction or combination therapy	Depends heavily on labeling and prescribing behavior
Formulation	Capsule composition, purity, stability or delivery system	Can block a specific product design
Manufacturing	Purification, esterification or encapsulation process	Usually more difficult to enforce against a finished-product manufacturer
U.S. 8,709,475	Statin plus high-dose ethyl eicosapentaenoate for mixed dyslipidemia	Combination-use and label-driven risk

The patent's commercial value is therefore linked to the prescribing environment. Its scope is meaningful for a product used at 4 grams per day in statin-treated patients, but it does not independently block every product containing icosapent ethyl.

Does biosimilar law apply to Vascepa?

No. Icosapent ethyl is a small-molecule drug, not a biologic. The relevant abbreviated pathway is an ANDA under section 505(j) of the Federal Food, Drug, and Cosmetic Act, not a biosimilar application under the Public Health Service Act.

The principal competitive risks are:

ANDA approval;
Paragraph IV litigation;
Label carve-outs;
Authorized-generic arrangements;
Patent settlements; and
Commercial substitution after state substitution laws apply.

Biosimilar concepts such as interchangeability, reference biologics and the 12-year biologics exclusivity period do not govern Vascepa.

What generic launch scenarios exist?

Launch after patent expiry

A generic applicant may accept a Paragraph III certification and await the relevant patent-expiration date. This reduces litigation exposure but delays commercial entry.

Launch after a successful Paragraph IV challenge

If the patent is invalidated, found unenforceable or held not infringed, FDA approval may proceed subject to other unexpired listed patents and regulatory requirements.

Label carve-out

A generic applicant may remove a patented indication from its labeling under the skinny-label framework. This strategy is more difficult where the remaining label still encourages the protected combination therapy.

Settlement or licensed entry

A settlement can establish a future launch date, an authorized generic arrangement or other commercial terms. Settlement analysis requires review of the specific agreement and any FTC or court filings.

At-risk launch

A generic may launch before final resolution, accepting potential damages and injunction risk. This scenario is uncommon where the branded company has a substantial remaining patent portfolio.

How strong is the patent estate around icosapent ethyl?

The estate is strongest when multiple patent categories overlap:

Product composition claims.
High-dose triglyceride-treatment claims.
Cardiovascular-risk-reduction claims.
Statin-combination claims.
Formulation and manufacturing claims.

U.S. Patent 8,709,475 is most relevant to the fourth category. Its practical strength is moderate to high against a generic label that expressly directs use of 2.5 to 5 grams per day with a statin for mixed dyslipidemia. Its strength is lower against a label limited to an indication that omits the claimed combination or disease description.

The outcome-dependent claims are narrower than claim 1. They may be useful as fallback claims if the broader combination claim is challenged, but they require proof of the specified relative lipid reductions.

What revenue exposure does this patent create?

The patent can affect revenue from patients who receive high-dose icosapent ethyl while taking a statin. It does not cover all Vascepa revenue automatically.

Revenue exposure depends on:

The proportion of prescriptions written for statin-treated patients;
The approved and marketed indication;
The generic label;
The Orange Book listing status;
The number of unexpired blocking patents;
The outcome of Paragraph IV litigation; and
The timing of any settlement entry date.

A generic entering with a narrow label may capture part of the market while leaving other protected uses subject to litigation. A broad label that instructs concurrent statin use creates greater induced-infringement exposure.

Key Takeaways

U.S. Patent 8,709,475 is a method-of-treatment patent covering a statin plus 2,500 mg to about 5,000 mg daily ethyl eicosapentaenoate.
Claim 1 is the principal commercial claim; claims 2 through 9 add lipid-reduction thresholds.
Claim 10 covers eight named statins, including atorvastatin, rosuvastatin and simvastatin.
Claims 11 and 12 cover administration in dosage units, including capsules, but do not create a detailed formulation patent.
The patent is relevant to 4-gram daily icosapent ethyl treatment in statin-treated patients.
Generic risk is driven by the ANDA label, Paragraph IV certifications and whether the label encourages the protected combination use.
Vascepa is a small-molecule drug, so biosimilar law does not apply.
The patent forms part of a broader icosapent ethyl estate that includes composition, method-of-use, formulation and manufacturing patents.
The patent's expected term falls in the 2030 period, subject to the official USPTO patent-term record.
Orange Book listing, exact patent expiration and litigation impact must be analyzed against NDA 202057 and the current FDA Orange Book record.

FAQs

Can a generic icosapent ethyl product avoid U.S. Patent 8,709,475 by using a lower dose?

Potentially. A product used below 2,500 mg per day would not satisfy the express dose limitation in claim 1, although other patents or approved-use claims could still apply.

Does prescribing a statin separately create infringement risk?

Yes. The claims do not require a fixed-dose combination product. Separate administration of a statin and ethyl eicosapentaenoate can still be relevant to direct or induced method infringement.

Does U.S. Patent 8,709,475 cover omega-3 mixtures containing DHA?

The claims identify ethyl eicosapentaenoate. A product based on a mixed EPA-DHA composition may not satisfy the active-ingredient limitation, but infringement depends on the actual formulation and claim construction.

Can a generic label omit the mixed-dyslipidemia indication?

A label carve-out may reduce risk under this patent, but the result depends on the remaining indications, dosing instructions and language encouraging statin combination therapy.

Is the 4-gram Vascepa dose within the patent claims?

Yes. A daily dose of 4,000 mg is within the claimed range of 2,500 mg to about 5,000 mg of ethyl eicosapentaenoate.

References

U.S. Patent No. 8,709,475. (2014). Methods of treating mixed dyslipidemia. United States Patent and Trademark Office.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.
U.S. Food and Drug Administration. (2019). FDA approves use of Vascepa to reduce cardiovascular risk in certain patients. FDA.
U.S. Food and Drug Administration. (2024). Vascepa prescribing information, NDA 202057. FDA.
Amarin Pharma, Inc. v. Hikma Pharmaceuticals USA Inc., 104 F.4th 1370 (Fed. Cir. 2024).
United States Code. (2024). 35 U.S.C. §§ 154, 271 and 282. Government Publishing Office.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Amarin Pharms	VASCEPA	icosapent ethyl	CAPSULE;ORAL	202057-001	Jul 26, 2012	AB	RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial				USE OF VASCEPA TO TREAT MIXED DYSLIPIDEMIA IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE (TG) LEVELS (>=150 MG/DL) AND ON STATIN THERAPY	⤷ Start Trial
Amarin Pharms	VASCEPA	icosapent ethyl	CAPSULE;ORAL	202057-002	Feb 16, 2017	AB	RX	Yes	No	⤷ Start Trial	⤷ Start Trial				USE OF VASCEPA TO TREAT MIXED DYSLIPIDEMIA IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE (TG) LEVELS (>=150 MG/DL) AND ON STATIN THERAPY	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2010241571	⤷ Start Trial
Brazil	PI1011876	⤷ Start Trial
Canada	2759284	⤷ Start Trial
China	102458109	⤷ Start Trial
China	104856985	⤷ Start Trial
Colombia	6470838	⤷ Start Trial
Cyprus	1119596	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 8,709,475

Which drugs does patent 8,709,475 protect, and when does it expire?

Summary for Patent: 8,709,475